foscarnet has been researched along with methotrexate in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 8 (50.00) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
Authors | Studies |
---|---|
Amano, O; Izeki, S; Kido, Y; Ogihara, T; Ono, A; Sai, Y; Satoh, E; Takanaga, H; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brink, NS; Goldstone, AH; Kottaridis, PD; Linch, DC; Mackinnon, S; McKeag, N; Peggs, KS; Preiser, W; Tedder, RS | 1 |
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
Ait Arkoub, Z; Arnulf, B; Chebbi, F; Fillet, AM; Lefrere, F; Varet, B | 1 |
Cerimele, F; Cesarman, E; Curreli, F; Flore, O; Friedman-Kien, AE; Muralidhar, S; Rosenthal, LJ | 1 |
Kobayashi, R; Matsumoto, Y; Nasu, T; Suzuki, D; Takanashi, K; Uetake, K | 1 |
Komoto, T; Mushiga, Y; Nagai, N; Ozawa, Y | 1 |
2 review(s) available for foscarnet and methotrexate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
14 other study(ies) available for foscarnet and methotrexate
Article | Year |
---|---|
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
Topics: Amino Acid Sequence; Animals; Benzoic Acid; Biological Transport; Carboxylic Acids; Carrier Proteins; Cell Line; Digestive System; Hydrogen-Ion Concentration; Immunohistochemistry; Intestinal Absorption; Lactic Acid; Molecular Sequence Data; Monocarboxylic Acid Transporters; Rats; Tissue Distribution; Transfection | 1999 |
Exploring the role of different drug transport routes in permeability screening.
Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Fluconazole; Foscarnet; Humans; Leukemia; Lymphoma; Male; Methotrexate; Middle Aged; Polymerase Chain Reaction; Postoperative Period; Prospective Studies; Risk; Survival Rate; Time Factors; Tissue Donors; Transplantation, Homologous | 2000 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Combined Modality Therapy; Cyclosporine; Cytarabine; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Fatal Outcome; Foscarnet; Graft vs Host Disease; Herpes Genitalis; Herpes Simplex; Humans; Hydroxyurea; Immunocompromised Host; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Simplexvirus; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cidofovir; Cytosine; Down-Regulation; Drug Resistance; Foscarnet; Herpesvirus 8, Human; Humans; Immediate-Early Proteins; Interleukin-6; Methotrexate; Neuropeptides; Nucleic Acid Synthesis Inhibitors; Open Reading Frames; Organophosphonates; Organophosphorus Compounds; Trans-Activators; Transcription, Genetic; Tumor Cells, Cultured; Viral Proteins; Virus Activation; Virus Latency; Virus Replication | 2002 |
Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Child; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarnet; Humans; Immunocompromised Host; Immunosuppressive Agents; L-Lactate Dehydrogenase; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Methylprednisolone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Retinal Detachment; Vincristine | 2012 |
Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report.
Topics: Adult; Epstein-Barr Virus Infections; Female; Foscarnet; Herpesvirus 4, Human; Humans; Methotrexate; Papilledema; Pulse Therapy, Drug; Retinitis; Steroids; Treatment Outcome | 2021 |